INTERPOLAR-prospective, interventional studies as part of the Medical Informatics Initiative to improve medication therapy safety in healthcare

• Published in: Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz Gesundheitsforschung, Gesundheitsschutz, 2024-06, Vol.67 (6), p.676
• Main Authors: Loeffler, Markus, Maas, Renke, Neumann, Daniel, Scherag, André
• Format: Article
• Language: ger
• Subjects: Drug-Related Side Effects and Adverse Reactions - prevention & control; Electronic Health Records; Germany; Humans; Medical Informatics; Medication Errors - prevention & control; Patient Safety; Prospective Studies; Quality Improvement
• ISSN: 1437-1588; 1437-1588
• DOI: 10.1007/s00103-024-03890-w

Medication analyses by ward pharmacists are an important measure of drug therapy safety (DTS). Medication-related problems (MRPs) are identified and resolved with the attending clinicians. However, staff resources for extended medication analyses and complete documentation are often limited. Until now, data required for the identification of risk patients and for an extended medication analysis often had to be collected from various parts of the institution's internal electronic medical record (EMR). This error-prone and time-consuming process is to be improved in the INTERPOLAR (INTERventional POLypharmacy-Drug interActions-Risks) project using an IT tool provided by the data integration centers (DIC).INTERPOLAR is a use case of the Medical Informatics Initiative (MII) that focuses on the topic of DTS. The planning phase took place in 2023, with routine implementation planned from 2024. DTS-relevant data from the EMR is to be presented and the documentation of MRPs in routine care is to be facilitated. The prospective multicenter, cluster-randomized INTERPOLAR‑1 study serves to evaluate the benefits of IT support in routine care. The aim is to show that more MRPs can be detected and resolved with the help of IT support. For this purpose, six normal wards will be selected at each of eight university hospitals, so that 48 clusters (with a total of at least 70,000 cases) are available for randomization.